Adventrx says independent studies show Thiovir inhibits influenza A

By Ted A. Knutson

Washington, Jan. 31 - Adventrx Pharmaceuticals, Inc. announced Tuesday a series of independent preclinical tests confirmed inhibition of influenza A virus by the company's broad spectrum anti-viral drug Thiovir.

Adventrx filed a provisional patent application with the U.S. Patent and Trademark Office on Friday in connection with these findings.

The company is conducting preclinical research on influenza A, which includes the H5N1 avian flu strain. The tests are being conducted in collaboration with Virapur, LLC, a virology specialty company in San Diego.

Thiovir is a broad-spectrum anti-viral agent and non-nucleoside reverse transcriptase inhibitor (NNRTI) designed for oral delivery and as a component of highly active antiretroviral therapy for HIV/AIDS.

"Additional confirmatory tests for Thiovir in avian flu and other viruses are planned. A preclinical package for Thiovir with extensive pharmacology and toxicology studies is already in development for our HIV program and we believe this would help expedite the clinical development of Thiovir for other indications, such as in the treatment of avian flu," said Joan M. Robbins, Ph.D., Adventrx chief scientific officer and executive vice president, in a news release.

Adventrx is a San Diego biopharmaceutical research and development company focused on developing new technologies for anticancer and antiviral treatments that improve performance and safety of existing drugs by addressing problems such as drug metabolism, toxicity, bioavailability and resistance.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.